Search results
Is It Too Late to Buy Vertex Pharmaceuticals Stock? | The Motley Fool
The Motley Fool· 2 hours agoVertex Pharmaceuticals (VRTX 1.36%) is a fast-growing pharmaceutical company that investors have...
Got $500? 3 Pharma Stocks to Buy and Hold Forever
The Motley Fool via AOL· 1 hour agoWith that in mind, let's examine three leading pharma stocks that are ripe for buying today and holding for the foreseeable future. 1. Vertex Pharmaceuticals Vertex ...
Vertex CEO Kewalramani sells over $6.7 million in company stock By Investing.com
Investing.com· 4 days agoVertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ:VRTX) CEO and President Reshma Kewalramani...
Vertex (VRTX) Outperforms Industry on Rapid Pipeline Progress
Zacks via Yahoo Finance· 5 days agoVertex Pharmaceuticals Incorporated VRTX has been benefiting from strong revenue growth, regulatory...
Insider Selling: Director Bruce Sachs Sells Shares of Vertex Pharmaceuticals Inc (VRTX)
GuruFocus.com via Yahoo Finance· 1 day agoOn May 22, 2024, Bruce Sachs, Director at Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale...
New Pain Drug Could Be Big For Vertex Stock As Shares Score Breakout
Investor's Business Daily· 2 days agoCystic fibrosis treatment leader Vertex Pharmaceuticals scored a breakout from a cup base the past...
Insider Sale: CEO & President Reshma Kewalramani Sells 15,202 Shares of Vertex ...
GuruFocus.com via Yahoo Finance· 4 days agoOn May 20, 2024, Reshma Kewalramani, CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX),...
2 Biotech Stocks to Buy in May
Motley Fool via Yahoo Finance· 1 day agoRegardless of what happens, investing in market leaders with robust underlying businesses and excellent prospects is still usually a good idea. Let's...
3 High-Flying Stocks That Could Soar Even More
The Motley Fool via AOL· 1 day agoHere's why they picked Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX). Just getting started Keith Speights (Eli Lilly): In 2023 ...
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow | The Motley Fool
The Motley Fool· 2 hours agoCRISPR's first commercialized product, a gene therapy called Casgevy, which treats or functionally cures both sickle cell disease (SCD) and beta thalassemia, is in the midst of its global rollout ...
